[Successful rituximab monotherapy in a patient with mucosa-associated lymphoid tissue lymphoma of the rectum with trisomy 3, 18]

Miwako Kagawa; Seisuke Okamura; Koichi Okamoto; Shinji Kitamura; Tetsuo Kimura; Miyako Niki; Masako Kaji; Toshiya Okahisa; Mitsuyasu Yano; Seiko Kagawa; Eiji Kudo; Toshiaki Sano; Yoshitaka Imoto; Satoshi Wada; Tetsuji Takayama

[Successful rituximab monotherapy in a patient with mucosa-associated lymphoid tissue lymphoma of the rectum with trisomy 3, 18]

Nihon Shokakibyo Gakkai Zasshi. 2010 Apr;107(4):612-9.

[Article in Japanese]

Authors

Miwako Kagawa¹, Seisuke Okamura, Koichi Okamoto, Shinji Kitamura, Tetsuo Kimura, Miyako Niki, Masako Kaji, Toshiya Okahisa, Mitsuyasu Yano, Seiko Kagawa, Eiji Kudo, Toshiaki Sano, Yoshitaka Imoto, Satoshi Wada, Tetsuji Takayama

Affiliation

¹ Department of Gastroenterology and Oncology, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan.

PMID: 20379095

Abstract

A 62-year-old man was referred to our hospital with enlargement of mucosa-associated lymphoid tissue (MALT) lymphoma of the rectum after the eradication of Helicobacter pylori. The patient was given a diagnosis of stage I MALT. Endoscopic observation revealed an enlarged rectal tumor with 3, 18 double trisomy. Rituximab monotherapy was given and complete remission was achieved. Rituximab monotherapy can be useful for MALT lymphoma of the rectum.

Publication types

Case Reports
English Abstract

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents / therapeutic use*
Chromosomes, Human, 1-3*
Chromosomes, Human, 16-18*
Humans
Lymphoma, B-Cell, Marginal Zone / drug therapy*
Male
Middle Aged
Rectal Neoplasms / drug therapy*
Remission Induction
Rituximab
Trisomy*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Rituximab